211 related articles for article (PubMed ID: 12779014)
21. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
22. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
24. Transplenic and transtumoral in vivo immunostimulation: effect on cellular immunity parameters.
Boura P; Kountouras J; Lygidakis NJ; Safioleas M; Aphinives P
Hepatogastroenterology; 1999; 46(26):799-803. PubMed ID: 10370616
[TBL] [Abstract][Full Text] [Related]
25. Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.
Velotti F; Tubaro A; Stoppacciaro A; Pettinato A; Morrone S; Bossola P; Napolitano T; Miano L; Ruco L; Piccoli M
Ann Ist Super Sanita; 1990; 26(3-4):411-21. PubMed ID: 2091503
[TBL] [Abstract][Full Text] [Related]
26. [IL-2 bronchoscopic istillation and immune cell activation: preliminary results of the BRIIL-2 study for treatment of pulmonary metastasis from renal cancer and melanoma].
Filippetti M; Torsello A; Cordiali Fei P; Bordignon V; Trento E; Tonachella R; Piperno G; Prignano G
Clin Ter; 2009; 160(2):139-43. PubMed ID: 19452104
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
Doehn Ch; Richter A; Lehmacher W; Jocham D
Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
[TBL] [Abstract][Full Text] [Related]
28. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
[TBL] [Abstract][Full Text] [Related]
29. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer.
Ramsey S; Aitchison M; Graham J; McMillan DC
BJU Int; 2008 Jul; 102(1):125-9. PubMed ID: 18336617
[TBL] [Abstract][Full Text] [Related]
30. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
31. Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores decreased monocyte HLA-DR expression after cardiopulmonary bypass.
Börgermann J; Friedrich I; Scheubel R; Kuss O; Lendemans S; Silber RE; Kreuzfelder E; Flohé S
Thorac Cardiovasc Surg; 2007 Feb; 55(1):24-31. PubMed ID: 17285470
[TBL] [Abstract][Full Text] [Related]
32. Effect of 2 anesthetic techniques on the postoperative proinflammatory and anti-inflammatory cytokine response and cellular immune function to minor surgery.
Schneemilch CE; Ittenson A; Ansorge S; Hachenberg T; Bank U
J Clin Anesth; 2005 Nov; 17(7):517-27. PubMed ID: 16297751
[TBL] [Abstract][Full Text] [Related]
33. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
34. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
[TBL] [Abstract][Full Text] [Related]
35. Changes in the levels of serum-soluble interleukin-2 receptor after surgical stress.
Murakami S; Sakata H; Tsuji Y; Okubo K; Takahashi T; Kikuchi M; Hirayama R
Surg Today; 2003; 33(8):565-70. PubMed ID: 12884092
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of renal cell carcinoma with mediastinal lymph node metastasis by interleukin-2: a case report.
Tokunaga M; Masuda A; Mukai M; Nakamura H; Iwaki K; Terachi T
Tokai J Exp Clin Med; 2005 Jul; 30(2):111-5. PubMed ID: 16146201
[TBL] [Abstract][Full Text] [Related]
37. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.
Vannier E; Kaser A; Atkins MB; Fantuzzi G; Dinarello CA; Mier JW; Tilg H
Eur Cytokine Netw; 1999 Mar; 10(1):37-42. PubMed ID: 10210771
[TBL] [Abstract][Full Text] [Related]
38. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration.
Lotze MT; Custer MC; Sharrow SO; Rubin LA; Nelson DL; Rosenberg SA
Cancer Res; 1987 Apr; 47(8):2188-95. PubMed ID: 3030546
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
[TBL] [Abstract][Full Text] [Related]
40. [Immunotherapy in radical surgery of colorectal carcinoma].
Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]